Document Detail

Xmn1-G γ polymorphism and clinical predictors of severity of disease in β-thalassemia intermedia.
MedLine Citation:
PMID:  21755589     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: To determine the prevalence of Xmn1-(G)γ polymorphism in North Indian children and adolescents with β thalassemia intermedia (TI) and to correlate it with disease severity.
METHODS: All patients of thalassemia intermedia presenting to the pediatric hematology clinic of a tertiary care hospital in North India were enrolled. Clinical severity of their disease was assessed by a phenotypic score proposed by Phadke and Agarwal. They were classified according to status of their Xmn1-(G)γ polymorphism as Xmn1-(G)γ +/+, Xmn1-(G)γ +/-, and Xmn1-(G)γ -/- by molecular analysis.
RESULTS: A total of 104 patients were enrolled. Severe TI was seen in 56.7% (59) patients, while 43.3% (45) had non-severe TI. Jaundice was more frequent in severe TI than in non-severe TI. Xmn1-(G)γ +/+ was present in 25.9% (25) patients. The frequency of the Xmn1-(G)γ +/- and Xmn1-(G)γ -/- was 22% and 37.3% in severe TI children. The corresponding frequencies were 31.1% and 42.2% in non-severe TI group respectively. No significant correlation was observed between the Xmn1-(G)γ polymorphism and severity of thalassemia, age at onset of symptoms, age at diagnosis, age at first transfusion, transfusion frequency or average hemoglobin levels. HbF level was significantly higher in Xmn1-(G)γ +/+ and Xmn1-(G)γ +/- patients.
CONCLUSIONS: This study showed that although the prevalence of Xmn1-(G)γ polymorphism is high in β thalassemia intermedia patients, it alone could not predict clinical severity in TI patients. Further refinement and validation of clinical scoring system is necessary for guiding appropriate management.
Sapna Oberoi; Reena Das; Inusha Panigrahi; Jasbir Kaur; Ram K Marwaha
Related Documents :
11705639 - The occurrence of a duodenal or gastric ulcer in two different populations living in th...
8976939 - Ulcer osteoma and periosteal reactions to chronic leg ulcers.
5428859 - Radiological anatomy after pyloroplasty.
22094909 - Impact of body mass index on clinical outcome in patients hospitalized with congestive ...
381739 - Characteristics of adrenocortical function, gastrin release and gastric secretion in du...
6609419 - Early- and late-onset duodenal ulcers in chinese and scots.
3661369 - Merits and limitations of quantitative treadmill exercise score.
14965579 - Management of patients with intermediate (c3) cytology and a solitary breast lump.
18682669 - The relationship between the breast arterial calcification detected by mammography and ...
Publication Detail:
Type:  Journal Article     Date:  2011-07-13
Journal Detail:
Title:  Pediatric blood & cancer     Volume:  57     ISSN:  1545-5017     ISO Abbreviation:  Pediatr Blood Cancer     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-09-12     Completed Date:  2012-01-06     Revised Date:  2012-02-28    
Medline Journal Info:
Nlm Unique ID:  101186624     Medline TA:  Pediatr Blood Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1025-8     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Wiley-Liss, Inc.
Department of Pediatrics, Pediatric Hematology-Oncology Unit, Advanced Pediatric Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, UT, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Child, Preschool
Deoxyribonucleases, Type II Site-Specific / metabolism*
Hemoglobins / genetics*,  metabolism*
Polymorphism, Genetic / genetics*
Predictive Value of Tests
Severity of Illness Index
beta-Thalassemia / diagnosis,  genetics*,  pathology*
Reg. No./Substance:
0/Hemoglobins; EC 3.1.21.-/endodeoxyribonuclease XmnI; EC, Type II Site-Specific

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Urgent radiotherapy is effective in the treatment of metastatic medulloblastoma causing symptomatic ...
Next Document:  Clinical advances in hemophilia management.